In US Drug Pricing Debate, ICER’s Voice Gets Louder
The Biggest Mistake For Pharma Is Failing To Engage With ICER
ICER’s influence on drug pricing, and policy, is growing. Spotlighting the worst drug price rises is one recent example.
You may also be interested in...
ICER's report on unsupported price increases highlighted seven drugs that cost the US health system $1.67bn due to price increases after rebates and other concessions.
The pandemic has brightened pharma’s image, but drug pricing is still high on the political agenda. For US and European politicians, the health crisis has heightened the tension between supporting innovation and controlling rising costs.
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?